TrianglePUBLICATIONS · 38828984
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- N Engl J Med
- Publication date
- 2024 Nov 7
- First author
- Blank CU
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Blank CU
- type
- Author
- name
- Lucas MW
- type
- Author
- name
- Scolyer RA
- type
- Author
- name
- van de Wiel BA
- type
- Author
- name
- Menzies AM
- type
- Author
- name
- Lopez-Yurda M
- type
- Author
- name
- Hoeijmakers LL
- type
- Author
- name
- Saw RPM
- type
- Author
- name
- Lijnsvelt JM
- type
- Author
- name
- Maher NG
- type
- Author
- name
- Pulleman SM
- type
- Author
- name
- Gonzalez M
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Blank CU
- type
- Author
- name
- Lucas MW
- type
- Author
- name
- Scolyer RA
- type
- Author
- name
- van de Wiel BA
- type
- Author
- name
- Menzies AM
- type
- Author
- name
- Lopez-Yurda M
- type
- Author
- name
- Hoeijmakers LL
- type
- Author
- name
- Saw RPM
- type
- Author
- name
- Lijnsvelt JM
- type
- Author
- name
- Maher NG
- type
- Author
- name
- Pulleman SM
- type
- Author
- name
- Gonzalez M
- type
- Author
- bibliography ids
- nci-bib-8a1f8c2bcd025a7a9cbb12cf
- book metadata
- content sha256
- fd6df2775e3b5c5592f7e3685fd0571251fd8b3d56542b4b224a2f8a3f23a4a5
- document type
- citation
- dois
- 10.1056/NEJMoa2402604
- electronic publication date
- display
- 2024 Jun 2
- precision
- day
- year
- 2024
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:38828984
- immutable id
- pubmed:38828984@fd6df2775e3b5c5592f7e3685fd0571251fd8b3d56542b4b224a2f8a3f23a4a5
- journal
- abbreviation
- N Engl J Med
- issn electronic
- 1533-4406
- issn print
- 0028-4793
- issue
- 18
- name
- The New England journal of medicine
- nlm unique id
- 0255562
- pages
- 1696-1708
- volume
- 391
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 38828984
- provenance
- batch id
- 3e43afde6f26fc8df6da
- provider
- NCBI PubMed ESummary
- record sha256
- af12634a729de41a0161696b10633b46fd1942e8174b40ae37c3034a781157ee
- response sha256
- fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
- retrieved at
- 2026-09-09T23:48:21.145285+00:00
- publication date
- display
- 2024 Nov 7
- precision
- day
- year
- 2024
- publication types
- Journal Article
- Randomized Controlled Trial
- Clinical Trial, Phase III
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Preserved source evidence · Not medical advice